Findings

What do systematic reviews say?

8 questions · 8 findings · 2 reviews · Cystic Fibrosis and Genetic Disorders

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 4 · 50%Low 3 · 37.5%Moderate 1 · 12.5%High 0 · 0%

Summary of findings: monoclonal antibody KB001‐A vs placebo

Pulmonary exacerbations · children (12 or over) and adults with cystic fibrosis and lung infection

Summary of findings: monoclonal antibody KB001‐A showed no clear difference in pulmonary exacerbations compared with placebo (low certainty).

1 finding from 1 review

Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes only
RR 0.25 [0.03, 2.4]
2 studies · 196 participants
Low

Summary of findings: monoclonal antibody KB001‐A vs placebo

Respiratory function number of episodes of a drop in FEV1 (unit of measurement not given) · children (12 or over) and adults with cystic fibrosis and lung infection

It is very uncertain whether summary of findings: monoclonal antibody KB001‐A changes respiratory function number of episodes of a drop in FEV1 (unit of… compared with placebo (very low certainty).

1 finding from 1 review

Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes only
RR 4.74 [0.28, 79.44]
2 studies · 196 participants
Very low

Summary of findings: monoclonal antibody KB001‐A vs placebo

Number experiencing adverse effects · children (12 or over) and adults with cystic fibrosis and lung infection

It is very uncertain whether summary of findings: monoclonal antibody KB001‐A changes adverse events number of participants experiencing adverse events compared with placebo (very low certainty).

1 finding from 1 review

Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes only
RR 1.3 [0.9, 1.87]
2 studies · 196 participants
Very low

Summary of findings: monoclonal antibody KB001‐A vs placebo

Need for antibiotics time to need for antibiotics · children (12 or over) and adults with cystic fibrosis and lung infection

Summary of findings: monoclonal antibody KB001‐A showed no clear difference in need for antibiotics time to need for antibiotics compared with placebo (moderate certainty).

1 finding from 1 review

Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes only
HR 1 [0.69, 1.45]
1 study · 169 participants
Moderate

Summary of findings: monoclonal antibody KB001‐A vs placebo

QoL · children (12 or over) and adults with cystic fibrosis and lung infection

1 finding from 1 review

Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 27 participants
Low

Summary of findings: monoclonal antibody KB001‐A vs placebo

Sputum microbiology · children (12 or over) and adults with cystic fibrosis and lung infection

1 finding from 1 review

Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 27 participants
Low

Summary of findings: monoclonal antibody KB001‐A vs placebo

Inflammatory markers · children (12 or over) and adults with cystic fibrosis and lung infection

1 finding from 1 review

Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 196 participants
Very low

Intervention not reported

Antibody production: number of participants developing IgG antibodies · adults and children with mucopolysaccharidosis I

It is very uncertain whether the intervention changes antibody production: number of participants developing IgG antibodies (very low certainty).

1 finding from 1 review

Enzyme replacement therapy with laronidase (Aldurazyme®) for treating mucopolysaccharidosis type I 2019 · Cochrane Headline outcomes only
OR 385.4 [17.47, 8500.51]
1 study · 45 participants
Very low